Nivalis Therapeutics, Inc. (NASDAQ: NVLS) is watching its shares crumble on Tuesday after the company gave an update on its mid-stage Cystic Fibrosis (CF) trial. Specifically, the company announced topline results from the its…
Shares of Genetic Technologies practically doubled in Tuesday's session after the company announced the signing of an exclusive worldwide license agreement with the University of Melbourne.
Cotiviti intends to offer 10 million shares in a secondary offering that could be valued up to more than $361 million.
Recro Pharma shares saw a handy gain on Monday after the company announced positive late-stage results on its acute postoperative pain treatment.
Shares of PhaseRx more than doubled on Monday after the company announced that it received a key FDA approval for its rare liver disorder treatment.
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
The November 15 short interest data have been compared with the previous figures, and short interest was mixed in the selected pharmaceutical stocks.
Juno Therapeutics Inc. (NASDAQ: JUNO) saw its shares hit a new 52-week low in Wednesday’s session after the company announced a clinical hold on its JCAR015 trial. The company announced that it has voluntarily…
Eli Lilly & Co. (NYSE: LLY) is watching its shares in free fall on Wednesday, not from any election or political concerns but a late-stage trial failure. As we have said time and again,…
Skyline Medical Inc. (NASDAQ: SKLN) is watching its shares more than double in Tuesday’s session after the company issued a key update for its prospective Canada sales. The company announced that it has received…
Amedica Corp. (NASDAQ: AMDA) is watching its shares drop on Tuesday despite receiving mixed news from the U.S. Food and Drug Administration, along with a new appointment to its management team. Although the FDA…
Oragenics Inc. (NYSEMKT: OGEN) saw its shares practically double late on Monday, and even continue climbing after the trading session ended, following an update from the U.S. Food and Drug Administration (FDA). The agency…
Myovant Sciences Ltd. (NYSE: MYOV) priced its initial public offering of 14.5 million common shares on October 27, 2016. Now its quiet period has come to an end and the analysts at firms in the…
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is watching its shares slide on Monday after the company gave an update on a recent clinical study. Essentially, the company announced that its Milestone clinical study did not…
Aclaris Therapeutics saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering.
